

VERSION WITH MARKINGS TO SHOW CHANGES MADE

1. (Amended) Use of tosylchloramide(s), tosylchloramide salt(s), their derivatives and/or decomposition products for manufacture of medicaments to treat [treating] diseases of the skin and mucous membranes as well as organs and tissues, except for treatment of retroviral-(HIV)-diseases and disinfection.

4. (Amended) Use according to [one of Claims 1 to 3] Claim 1, characterized in that the diseases and/or efflorescences may be caused by microorganisms and/or accompanied by microorganisms.

5. (Amended) Use according to [one of Claims 1 to 4] Claim 1, characterized in that the diseases constitute parasitic diseases, in particular scabies, pediculosis or creeping eruption.

6. (Amended) Use according to [at least one of the preceding Claims] Claim 1, characterized in that the diseases affect:
 - a) the eye, in particular the lid, conjunctiva or cornea of the eye;
 - b) the ear, in particular the exterior of the ear;
 - c) the nose, in particular the nasal cavity;
 - d) the lips and mucous membranes of the mouth and/or the tongue;
 - e) the vulva and/or vagina;
 - f) the penis, in particular the glans penis and the prepuce;
 - g) the anus;
 - h) the nail, in particular the body of the nail, the wall and fold of the nail as well as the root of the nail;
 - i) the hair, in particular the hair follicles and the sebaceous glands and
 - j) the hands and feet, in particular the spaces between the fingers and toes.

7. (Amended) Use according to [at least one of the preceding Claims] Claim 1, characterized in that the tosylchloramide(s), tosylchloramide salt(s), their derivatives and/or decomposition products are present in the employed base in an amount of approximately 0.1 to 20% by weight[, preferably approximately 5 to 15% by weight, in particular approximately 8 to 12% by weight].
8. (Amended) Use according to [at least one of the preceding Claims] Claim 1, characterized in that a tosylchloramide salt is employed, in particular chloramine T.
9. (Amended) Use according to [at least one of the preceding Claims] Claim 7, characterized in that the base constitutes a liquid, semi-solid or solid, water-containing or water-free galenic preparation.
10. (Amended) Use according to Claim 9, characterized in that the base constitutes an ointment, a gel, a cream, a paste, a suppository, such as a vaginal suppository, an adhesive bandage, a tablet, such an effervescent or vaginal tablet, or a capsule, a stick, a pulverized substance, a powder, a solution, an aerosol, a two-compartment system or a suspension, such as a shake mixture/dry suspension.
11. (Amended) Use according to Claim 9 [or 10], characterized in that the base constitutes a dosed aerosol or a dosed solution.
12. (Amended) Use according to Claim 9 [or 10], characterized in that the base constitutes a bath water additive.
13. (Amended) Use according to Claim 9 [or 10], characterized in that the salve is an O/W- or a W/O-emulsion ointment.

14. (Amended) Use according to [at least one of the preceding Claims] Claim 7, characterized in that the base is a cortisone-containing preparation, containing the tosylchloramide(s), tosylchloramide salt(s), their derivatives and/or decomposition products in an amount of approximately 0.1 to 20% by weight.

15. (Amended) Use according to Claim 9 [or 10], characterized in that the base is a gel, in which are present the tosylchloramide(s), tosylchloramide salt(s), their derivatives and/or decomposition products in an amount of approximately 0.1 to 5% by weight[, in particular approximately 0.1 to 2% by weight].

16. (Amended) Use according to Claim 9 [or 10], characterized in that the bath water additive is employed in form of pulverized substance or bath salt tablet or effervescent tablet, which is applied in water in a concentration of approximately 0.1 to 1% by weight.

Please add the following new claims:

17. Use according to Claim 1, characterized in that the tosylchloramide(s), tosylchloramide salt(s), their derivatives and/or decomposition products are present in the employed base in an amount of approximately 5 to 15% by weight.

18. Use according to Claim 1, characterized in that the tosylchloramide(s), tosylchloramide salt(s), their derivatives and/or decomposition products are present in the employed base in an amount of approximately 8 to 12% by weight.

19. Use according to Claim 9, characterized in that the base is a gel, in which are present the tosylchloramide(s), tosylchloramide salt(s), their derivatives and/or decomposition products in an amount of approximately 0.1 to 2% by weight.